MedTrace Logo

Olanzapine for Cancer Related Anorexia-cachexia Syndrome

NCT06517199 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2024-07-24

No results posted yet for this study

Summary

Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.

Conditions

  • Anorexia
  • Cachexia

Interventions

DRUG

Olanzapine 2.5 MG

olanzapine 2.5 mg/day for 28 days

DRUG

Olanzapine 5 MG

olanzapine 5 mg/day for 28 days

DRUG

Placebo

placebo 1 tab/day for 28 days

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-22
Primary Completion
2026-01-21
Completion
2026-01-21

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06517199 on ClinicalTrials.gov